The Activist Investor goal is to buy shares before they soar: investing in activist campaign stocks that have been sold off to their lowest levels… then benefit as these companies begin to turn around and prosper.
People thought I was crazy in 2008 when I predicted the collapse of Fannie Mae, Freddie Mac, and General Motors. People thought I was crazy in late 2008 when I said the biggest mall owner in America and one of the biggest newspapers would go bust. People thought I was crazy when I said we’d
A wave of AI skepticism has emerged from Wall Street and the mainstream financial media. Despite two years of hype, it is not living up to its promises of creating more revenue and productivity.
Artificial intelligence has caused this company’s revenues to plummet – the price of its bonds to fall. Now, it’s fighting back, by flipping the story and using AI to create a better product. Whether or not it succeeds, investors will very likely get paid anyway.
Editor’s Note: This month our Spotlight is focused on Dave Lashmet, the man Porter calls “the best technology investor of the last 25 years.” In last week’s issue (click here if you missed it), we explored the next phase of the GLP-1 weight- loss revolution and showed you how to profit from one of the most important drug
This month’s issue of Biotech Frontiers focuses on a fast follower whose stock is poised to soar because it has a better version of a successful medicine… which it has also, strategically, chosen to make available at a better price.
To honor Independence Day, we’ve put together a special report… about your right to wealth. To pursue it, create it, keep it, compound it, and pass it on to your children and grandchildren.
Editor’s Note: Today marks the inaugural issue of our newest membership benefit, The Porter & Co. Spotlight. If you missed our announcement explaining the Spotlight, you can read it here. On Mondays we’ll turn the spotlight outside of Porter & Co. We’ll bring you exclusive access to the research, the thinking, and the investment ideas of the analysts who Porter follows. Each
Porter sits down and discusses the future of the biotech industry in this in-depth conversation with his long-time friend and former professor, biotech expert Dave Lashmet.